Revenue - Condensed Statement Of Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Development and Collaboration Agreement
Revenue from collaborative arrangements	$ 11,463	$ 26,464	$ 31,245
Viatris collaboration agreement
Development and Collaboration Agreement
Revenue from collaborative arrangements	$ 43,848	43,893	13,664
Collaboration Loss			1,582
YUPELRI Monotherapy
Development and Collaboration Agreement
Percentage of net sales	35.00%
YUPELRI Monotherapy | Viatris collaboration agreement
Development and Collaboration Agreement
Revenue from collaborative arrangements	$ 56,700	$ 50,000	$ 19,300
Percentage of net sales	35.00%	35.00%	35.00%